Tesamorelin

Tesamorelin is a stabilized version of the body's growth-hormone-releasing signal, engineered to last longer and target deep belly fat.

It's studied in weight and metabolic research — how growth-hormone signals reduce visceral fat and liver triglycerides.

Phase 3 trials showed real reductions in visceral fat in a specific patient group. That's an established result for the approved product.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

Tesamorelin is the active ingredient in FDA-approved Egrifta. BBOHC material is a research powder for lab evaluation only.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Glucose intolerance and mild peripheral swelling reported in trials.

• Falutz J et al. Effects of tesamorelin in HIV-infected patients with abdominal fat. N Engl J Med. 2007.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.